Why is China biotech deal flow holding up despite wobbling stocks?

BioPharma Dive’s Sept. 4, 2026 roundup said China-linked biotech deals are still moving at a steady pace even as two unnamed mid-cap biotechs saw sharp stock declines. The article frames this as a split between durable demand for external innovation and uneven public-market sentiment, while noting Eli Lilly is leading pharma dealmaking this year.